{"disease":{"id":"urogenital-neoplasms","name":"urogenital neoplasms"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04679675","title":"Self-Testing Options in the Era of Primary HPV Screening for Cervical Cancer Trial","phase":"NA","overall_status":"COMPLETED","enrollment_count":32771,"lead_sponsor_name":"Kaiser Permanente","has_results":true},{"nct_id":"NCT04923178","title":"A Multi-Center Natural History of Urothelial Cancer and Rare Genitourinary Tract Malignancies","phase":"","overall_status":"RECRUITING","enrollment_count":1100,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT06785636","title":"Open-Label Study of Pocenbrodib Alone and in Combination With Abiraterone Acetate, Olaparib, or 177Lu-PSMA-617","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":252,"lead_sponsor_name":"Pathos AI, Inc.","has_results":false},{"nct_id":"NCT04435964","title":"Gender Difference in sidE eFfects of ImmuNotherapy: a Possible Clue to Optimize cancEr tReatment","phase":"","overall_status":"COMPLETED","enrollment_count":247,"lead_sponsor_name":"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano","has_results":false},{"nct_id":"NCT05887245","title":"Clinical Significance of Adherent Perinephric Fat in Patients Undergoing Partial Nephrectomy","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":200,"lead_sponsor_name":"Centre of Postgraduate Medical Education","has_results":false},{"nct_id":"NCT03344757","title":"Health Gatherings - For Your Health After Cancer","phase":"NA","overall_status":"COMPLETED","enrollment_count":188,"lead_sponsor_name":"University of Miami","has_results":true},{"nct_id":"NCT07038369","title":"A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":134,"lead_sponsor_name":"Atavistik Bio, Inc","has_results":false},{"nct_id":"NCT04462926","title":"Evaluation of Diagnostic Accuracy of [68Ga]Ga-PSMA-11 PET/CT in Primary Staging of Intermediate and High Risk Prostatic Cancer in Men Newly Diagnosed","phase":"NA","overall_status":"UNKNOWN","enrollment_count":100,"lead_sponsor_name":"Azienda Ospedaliero-Universitaria di Modena","has_results":false},{"nct_id":"NCT04235777","title":"Bintrafusp Alfa (M7824) and PDS01ADC Alone and in Combination With Stereotactic Body Radiation Therapy (SBRT) in Adults With Metastatic Non-Prostate Genitourinary Malignancies","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT06237920","title":"Stage II-IIIa Urothelial Cancer Randomizing Pre-operative Nivolumab With or Without Relatlimab","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":90,"lead_sponsor_name":"The Netherlands Cancer Institute","has_results":false},{"nct_id":"NCT05413850","title":"Anti-tumour Activity of (177Lu) rhPSMA-10.1 Injection","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":82,"lead_sponsor_name":"Blue Earth Therapeutics Ltd","has_results":false},{"nct_id":"NCT04566952","title":"Anlotinib Combined With Dose-reduced Olaparib in Patients With Platinum-Sensitive Recurrent Ovarian Cancer","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":68,"lead_sponsor_name":"Xiaoxiang Chen","has_results":false},{"nct_id":"NCT04461509","title":"High Resolution, 18F-PSMA PET-MRI Before Prostate Cancer HIFU or Radical Prostatectomy","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":62,"lead_sponsor_name":"Alessandro D'Agnolo","has_results":true},{"nct_id":"NCT05030077","title":"Anlotinib Combined With Platinum/Gemcitabine for First Line Treatment of Advanced Urothelial Carcinoma","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":53,"lead_sponsor_name":"Tianjin Medical University Second Hospital","has_results":false},{"nct_id":"NCT04249947","title":"P-PSMA-101 CAR-T Cells in the Treatment of Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Advanced Salivary Gland Cancers (SGC)","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":40,"lead_sponsor_name":"Poseida Therapeutics, Inc.","has_results":false},{"nct_id":"NCT03562897","title":"Evaluation of Ocoxin-Viusid® in Advanced or Metastatic Ovarian Epithelial Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":40,"lead_sponsor_name":"Catalysis SL","has_results":false},{"nct_id":"NCT06676527","title":"Vorolanib in the Second-line Treatment of Patients With Unresectable or Metastatic Renal Cell Carcinoma","phase":"","overall_status":"RECRUITING","enrollment_count":39,"lead_sponsor_name":"Jinling Hospital, China","has_results":false},{"nct_id":"NCT03636256","title":"Evaluation of NanoDoce® in Participants With Urothelial Carcinoma","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":36,"lead_sponsor_name":"NanOlogy, LLC","has_results":true},{"nct_id":"NCT04556071","title":"Efficacy and Safety of Niraparib Combined With Bevacizumab in Platinum Refractory/Resistant Recurrent Ovarian Cancer","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":32,"lead_sponsor_name":"Xiaoxiang Chen","has_results":false},{"nct_id":"NCT04644432","title":"Individualized Treatment Strategy for Patients With Metastatic Non-clear Cell Renal Cell Carcinoma","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":30,"lead_sponsor_name":"Herlev and Gentofte Hospital","has_results":false},{"nct_id":"NCT03551457","title":"Potential Therapeutic Response In Urogenital Tumors","phase":"","overall_status":"COMPLETED","enrollment_count":30,"lead_sponsor_name":"University of Campinas, Brazil","has_results":false},{"nct_id":"NCT06353906","title":"Carboplatin/Paclitaxel + Pembrolizumab for Locoregionally Advanced Penile Cancer","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":27,"lead_sponsor_name":"The Netherlands Cancer Institute","has_results":false},{"nct_id":"NCT05935748","title":"Ph2 Study NKT2152 With Palbociclib & Sasanlimab in Subjects With Advanced Clear Cell Renal Cell Carcinoma (ccRcc)","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":18,"lead_sponsor_name":"NiKang Therapeutics, Inc.","has_results":false},{"nct_id":"NCT03081858","title":"Proliposomal Intravesical Paclitaxel for Treatment of Low-Grade, Stage Ta, Non Muscle Invasive Bladder Cancer","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":15,"lead_sponsor_name":"Lipac Oncology LLC","has_results":true},{"nct_id":"NCT06706921","title":"18F-Fluciclovine PET/CT Impact on Predicting Clinical Outcome of 177Lu-PSMA-617 Therapy in Patients With Prostate Cancer","phase":"PHASE4","overall_status":"RECRUITING","enrollment_count":15,"lead_sponsor_name":"VA Greater Los Angeles Healthcare System","has_results":false},{"nct_id":"NCT04221828","title":"Trial of NanoPac Focal Therapy for Prostate Cancer","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":1,"lead_sponsor_name":"NanOlogy, LLC","has_results":true},{"nct_id":"NCT01217697","title":"Study of Abiraterone Acetate in Patients With Advanced Prostate Cancer","phase":"","overall_status":"APPROVED_FOR_MARKETING","enrollment_count":null,"lead_sponsor_name":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","has_results":false},{"nct_id":"NCT04060628","title":"Expanded Access to NanoDoce","phase":"","overall_status":"NO_LONGER_AVAILABLE","enrollment_count":null,"lead_sponsor_name":"NanOlogy, LLC","has_results":false}],"total":28},"guidelines":[],"source":"Drug Landscape verified database"}